CY1116800T1 - Συνθεσεις και μεθοδοι χρησης για θεραπευτικα αντισωματα - Google Patents

Συνθεσεις και μεθοδοι χρησης για θεραπευτικα αντισωματα

Info

Publication number
CY1116800T1
CY1116800T1 CY20151100934T CY151100934T CY1116800T1 CY 1116800 T1 CY1116800 T1 CY 1116800T1 CY 20151100934 T CY20151100934 T CY 20151100934T CY 151100934 T CY151100934 T CY 151100934T CY 1116800 T1 CY1116800 T1 CY 1116800T1
Authority
CY
Cyprus
Prior art keywords
antibodies
compositions
methods
therapeutic antibodies
baffr
Prior art date
Application number
CY20151100934T
Other languages
English (en)
Inventor
Christoph Heusser
Julia Neugebauer
Eveline Schaadt
Stefanie Urlinger
Maximilian Woisetschlaeger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41073830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1116800(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1116800T1 publication Critical patent/CY1116800T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Αντισώματα τα οποία δεσμεύονται συγκεκριμένα στον υποδοχέα BAFF (BAFFR). Πιο συγκεκριμένα, αντισώματα που είναι ανταγωνιστές BAFFR με in vivo δραστηριότητα μείωσης των Β-κυττάρων και συνθέσεις και μεθόδους για χρήση των εν λόγω αντισωμάτων για τη θεραπεία παθολογικών διαταραχών που μπορούν να θεραπευτούν με τη θανάτωση ή τη μείωση των Β-κυττάρων, όπως είναι ο συστημικός ερυθηματώδης λύκος ή η ρευματοειδής αρθρίτιδα ή άλλες αυτοάνοσες νόσοι ή λεμφώματα, λευχαιμίες και μυελώματα.
CY20151100934T 2008-07-17 2015-10-19 Συνθεσεις και μεθοδοι χρησης για θεραπευτικα αντισωματα CY1116800T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08160671 2008-07-17
EP09160326 2009-05-15
EP09797499.2A EP2315780B8 (en) 2008-07-17 2009-07-15 Compositions and methods of use for therapeutic antibodies

Publications (1)

Publication Number Publication Date
CY1116800T1 true CY1116800T1 (el) 2017-03-15

Family

ID=41073830

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100934T CY1116800T1 (el) 2008-07-17 2015-10-19 Συνθεσεις και μεθοδοι χρησης για θεραπευτικα αντισωματα

Country Status (41)

Country Link
US (3) US8106163B2 (el)
EP (1) EP2315780B8 (el)
JP (2) JP5767109B2 (el)
KR (2) KR101545795B1 (el)
CN (1) CN102119174B (el)
AR (1) AR072749A1 (el)
AU (1) AU2009272771B2 (el)
BR (1) BRPI0915928B8 (el)
CA (1) CA2730063C (el)
CL (1) CL2011000086A1 (el)
CR (1) CR11863A (el)
CU (1) CU23878B1 (el)
CY (1) CY1116800T1 (el)
DK (1) DK2315780T3 (el)
DO (1) DOP2011000016A (el)
EA (1) EA024492B1 (el)
EC (1) ECSP11010761A (el)
ES (1) ES2547270T3 (el)
GE (1) GEP20146129B (el)
HK (1) HK1150839A1 (el)
HR (1) HRP20151227T1 (el)
HU (1) HUE025778T2 (el)
IL (1) IL210485A (el)
JO (1) JO3149B1 (el)
MA (1) MA32481B1 (el)
MX (1) MX2011000616A (el)
MY (1) MY158980A (el)
NI (1) NI201100017A (el)
NZ (1) NZ590057A (el)
PE (1) PE20110563A1 (el)
PL (1) PL2315780T3 (el)
PT (1) PT2315780E (el)
RS (1) RS54299B1 (el)
SG (1) SG193805A1 (el)
SI (1) SI2315780T1 (el)
SM (1) SMP201100010B (el)
SV (1) SV2011003807A (el)
TW (1) TWI508742B (el)
UY (1) UY31987A (el)
WO (1) WO2010007082A1 (el)
ZA (1) ZA201008952B (el)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US20090176654A1 (en) * 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US9458240B2 (en) * 2010-12-10 2016-10-04 Novartis Pharma Ag Anti-BAFFR antibody formulations
JP2012153788A (ja) * 2011-01-25 2012-08-16 Nitto Denko Corp 光学用粘着シート
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
WO2015100246A1 (en) 2013-12-24 2015-07-02 Ossianix, Inc. Baff selective binding compounds and related methods
EA033604B1 (ru) 2014-01-31 2019-11-08 Boehringer Ingelheim Int Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CN114920840A (zh) 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
EP3964528A1 (en) 2015-07-29 2022-03-09 Novartis AG Combination therapies comprising antibody molecules to lag-3
AU2016369537B2 (en) 2015-12-17 2024-03-14 Novartis Ag Antibody molecules to PD-1 and uses thereof
WO2017118965A1 (en) 2016-02-10 2017-07-13 Novartis Ag Use of inhibitors of the activity or function of pi3k for the treatment of primary sjögren's syndrome
CN116041514A (zh) * 2016-06-06 2023-05-02 希望之城 Baff-r抗体及其用途
US11197928B2 (en) 2017-01-13 2021-12-14 Board Of Regents, The University Of Texas System Sustained production of high affinity antigen specific antibody by high dose BAFF receptor-targeting mAb-siRNA conjugate
AU2018271915A1 (en) * 2017-05-24 2019-11-28 Als Therapy Development Institute Therapeutic anti-CD40 ligand antibodies
CN117866097A (zh) * 2017-06-20 2024-04-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
JP7439046B2 (ja) * 2018-07-20 2024-02-27 テネオツー・インコーポレイテッド Ｃｄ１９に結合する重鎖抗体
JPWO2020202839A1 (el) * 2019-03-29 2020-10-08
KR20220093347A (ko) 2019-11-06 2022-07-05 노파르티스 아게 쇼그렌 증후군의 치료
CN112813099A (zh) * 2019-11-15 2021-05-18 上海细胞治疗集团有限公司 一种在活化的t细胞中具有高活性的启动子
CN116133687A (zh) 2020-08-04 2023-05-16 诺华股份有限公司 B细胞恶性肿瘤的治疗
CN116096414A (zh) 2020-08-04 2023-05-09 诺华股份有限公司 Cll的治疗
CN114149504B (zh) * 2020-09-07 2024-01-12 白先宏 Baff-r结合分子及其应用
IL302412A (en) 2020-11-06 2023-06-01 Novartis Ag Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies
CN115073598B (zh) * 2021-03-15 2024-02-20 盛禾(中国)生物制药有限公司 一种抗baffr抗体及其应用
CA3216063A1 (en) 2021-05-04 2022-11-10 Novartis Ag Treatment for lupus nephritis using anti-baffr antibodies
IL308044A (en) 2021-05-04 2023-12-01 Novartis Ag Treatment of systemic lupus erythematosus using antibuffer antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1210425T4 (en) * 1999-08-17 2015-08-10 Apotech R & D Sa BAFF receptor (BCMA), an immunoregulatory agent
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
JP2008526205A (ja) * 2004-12-31 2008-07-24 ジェネンテック・インコーポレーテッド Ｂｒ３に結合するポリペプチド及びその使用
WO2008008482A2 (en) * 2006-07-13 2008-01-17 Genentech, Inc. Altered br3-binding polypeptides

Also Published As

Publication number Publication date
BRPI0915928B8 (pt) 2021-05-25
US20100021452A1 (en) 2010-01-28
NZ590057A (en) 2012-08-31
GEP20146129B (en) 2014-08-11
JP6077587B2 (ja) 2017-02-08
EP2315780B8 (en) 2015-09-23
CU23878B1 (es) 2013-04-19
HK1150839A1 (en) 2012-01-13
KR101545795B1 (ko) 2015-08-19
UY31987A (es) 2010-02-26
EA024492B1 (ru) 2016-09-30
SMAP201100010A (it) 2011-05-06
US20120183529A1 (en) 2012-07-19
CU20110013A7 (es) 2012-06-21
PL2315780T3 (pl) 2016-01-29
DOP2011000016A (es) 2011-02-15
JP2015133983A (ja) 2015-07-27
JO3149B1 (ar) 2017-09-20
KR20110020914A (ko) 2011-03-03
WO2010007082A1 (en) 2010-01-21
CL2011000086A1 (es) 2011-07-01
EP2315780A1 (en) 2011-05-04
CA2730063C (en) 2017-04-18
CN102119174A (zh) 2011-07-06
US9340620B2 (en) 2016-05-17
AU2009272771A1 (en) 2010-01-21
ZA201008952B (en) 2012-01-25
RS54299B1 (en) 2016-02-29
CA2730063A1 (en) 2010-01-21
CN102119174B (zh) 2015-01-21
SG193805A1 (en) 2013-10-30
MA32481B1 (fr) 2011-07-03
JP2011527896A (ja) 2011-11-10
KR20130098432A (ko) 2013-09-04
HUE025778T2 (en) 2016-05-30
ECSP11010761A (es) 2011-02-28
AU2009272771B2 (en) 2012-09-20
SMP201100010B (it) 2011-09-09
NI201100017A (es) 2012-08-17
TWI508742B (zh) 2015-11-21
EP2315780B1 (en) 2015-08-19
BRPI0915928B1 (pt) 2020-10-20
MX2011000616A (es) 2011-02-24
PE20110563A1 (es) 2011-08-29
US20120195913A1 (en) 2012-08-02
SV2011003807A (es) 2011-03-23
BRPI0915928A2 (pt) 2015-11-03
MY158980A (en) 2016-11-30
IL210485A0 (en) 2011-03-31
HRP20151227T1 (hr) 2015-12-18
IL210485A (en) 2015-03-31
TW201006493A (en) 2010-02-16
AR072749A1 (es) 2010-09-15
US8106163B2 (en) 2012-01-31
US9382326B2 (en) 2016-07-05
JP5767109B2 (ja) 2015-08-19
SI2315780T1 (sl) 2015-11-30
ES2547270T3 (es) 2015-10-05
CR11863A (es) 2011-02-11
PT2315780E (pt) 2015-11-30
DK2315780T3 (en) 2015-10-19
EA201100191A1 (ru) 2011-08-30
KR101314369B1 (ko) 2013-10-10

Similar Documents

Publication Publication Date Title
CY1116800T1 (el) Συνθεσεις και μεθοδοι χρησης για θεραπευτικα αντισωματα
CY1120154T1 (el) Παραγωγα πιπεριδιν-4-υλ αζετιδινης ως αναστολεις jak1
CY1119664T1 (el) Συνθεσεις και μεθοδοι αυξησης της μυϊκης αναπτυξης
CY1119960T1 (el) Μεθοδοι για την αυξηση της αποτελεσματικοτητας της folr1 θεραπειας του καρκινου
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
EA201100524A1 (ru) Азаиндазолы в качестве антагонистов рецептора ccr1
EA201101009A1 (ru) АНТАГОНИСТЫ C5aR
EA201070148A1 (ru) Соединения и способы модулирования фарнезоидного рецептора x (fxr)
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
CL2012003604A1 (es) Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros.
ATE544767T1 (de) Triazoloä4,5-düpyramidinderivate und deren verwendung als purinrezeptorantagonisten
EA201590590A1 (ru) Модуляторы рецептора андрогенов и их применение
TR201901886T4 (tr) DNA-PK inhibitörleri.
EA201101709A1 (ru) Полициклические антагонисты рецепторов лизофосфатидной кислоты
EA201390821A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты и их применение
EA201171081A1 (ru) Производные индола в качестве антагонистов рецептора crth2
UA108222C2 (xx) СПОЛУКИ ЗАМІЩЕНОГО N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗОЛ$1,2-а]ПІРИДИН-3-КАРБОКСАМІДУ ЯК ІНГІБІТОРИ cFMS
EA200800835A1 (ru) Циклопропиламины в качестве модуляторов рецептора гистамина н
EA201290355A1 (ru) Спиропиперидиновые соединения в качестве антагонистов рецептора orl-1
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.
ECSP099675A (es) Compuestos heterocíclicos, composición y métodos de uso
EA201070637A1 (ru) Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н
EA201001872A1 (ru) Новые способы получения производных циклопропиламида
EA201490938A1 (ru) Производные спиротиенопиранпиперидина в качестве антагонистов рецептора orl-1 для применения для лечения алкогольной зависимости и злоупотребления алкоголем
CO6341571A2 (es) Composiciones y metodos de uso para anticuerpos terapeuticos